2014

C4 Imaging Announces First Sirius™ Positive Signal MRI Marker Implant

HOUSTON, April 7, 2014 /PRNewswire/ -- C4 Imaging LLC is pleased to announce the first patient implant with Sirius™, its novel positive-signal MRI Marker. Sirius™ is used following treatment of prostate cancer with brachytherapy to facilitate seed localization within the prostate, utilizing a single post-implant Magnetic Resonance (MR) imaging procedure. The first implant was performed at The University of Texas MD Anderson Cancer Center (Houston, Texas) and was used during a procedure with IsoRay™ Medical's Cesium-131 seeds.

"This first implant is a significant milestone," said Andrew Bright, President and CEO of C4 Imaging. "MR imaging of the implanted Sirius™ MRI Markers was successful and the clinical team were able to localize the implanted seeds."  He added, "We were delighted to partner with IsoRay™ Medical for this first implant. IsoRay are leading innovators in the use of brachytherapy to treat prostate cancer, as well as many other tumors, and recognize the potential of MR imaging to optimize treatment quality and patient care."

IsoRay CEO Dwight Babcock commented, "We are very excited to have our Cesium-131 isotope seeds chosen to partner with C4 Imaging's innovative positive-signal MRI Markers in the treatment of prostate cancer. This combines two of the newest technologies available in brachytherapy with the goal of improving patient outcomes."

Brachytherapy, or radioactive seed implantation, is a standard option for the curative treatment of prostate cancer. Brachytherapy involves implanting around 100 radioactive seeds into the prostate. Its popularity has increased due to its effectiveness, convenience, relatively low incidence of erectile dysfunction, and minimal invasiveness [1]. Radiation released from the seeds penetrates the surrounding prostate tissue at a limited distance, with most of the radiation concentrated within the prostate. Outcomes after brachytherapy can be excellent but depend greatly on the quality of the implant: 8-year prostate-specific antigen (PSA) relapse-free survival rates of 93% for high-quality implants vs. 76% for low-quality ones have been reported [2].

About C4 IMAGING

C4 Imaging LLC develops medical devices that enable clinicians to more accurately perform image-guided procedures. The company's core proprietary technology, C4, has been developed as Sirius™ the first commercially available Positive-Signal MRI Marker. Further information is available at www.c4imaging.com

For further information please contact:

Andrew Bright
President and CEO
C4 Imaging
Tel: 609 933 5895
abright@c4imaging.com

Copyright © 2014
Sirius is a trademark of C4 Imaging.
IsoRay is a trademark of IsoRay Medical.

References

  1. Frank SJ, et al. American College of Radiology Appropriateness Criteria Permanent Source Brachytherapy for Prostate Cancer. Brachytherapy. 2011; 10(5): 357-362.
  2. Zelefsky MJ, et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int. J. Radiat. Oncol. Biol. Phys. 2007; 67(2): 327-333.

SOURCE C4 Imaging



RELATED LINKS
http://www.c4imaging.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.